SK Biopharmaceuticals Statistics

Total Valuation

KRX:326030 has a market cap or net worth of KRW 7.28 trillion. The enterprise value is 7.16 trillion.

Market Cap	7.28T
Enterprise Value	7.16T

Important Dates

The last earnings date was Friday, May 9, 2025.

Earnings Date	May 9, 2025
Ex-Dividend Date	n/a

Share Statistics

KRX:326030 has 78.31 million shares outstanding.

Current Share Class	78.31M
Shares Outstanding	78.31M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.02%
Owned by Institutions (%)	14.22%
Float	28.06M

Valuation Ratios

The trailing PE ratio is 28.99 and the forward PE ratio is 42.82.

PE Ratio	28.99
Forward PE	42.82
PS Ratio	12.60
PB Ratio	12.31
P/TBV Ratio	13.05
P/FCF Ratio	74.05
P/OCF Ratio	73.00
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 72.24, with an EV/FCF ratio of 72.83.

EV / Earnings	28.51
EV / Sales	12.39
EV / EBITDA	72.24
EV / EBIT	87.93
EV / FCF	72.83

Financial Position

The company has a current ratio of 1.84, with a Debt / Equity ratio of 0.21.

Current Ratio	1.84
Quick Ratio	1.34
Debt / Equity	0.21
Debt / EBITDA	0.96
Debt / FCF	1.27
Interest Coverage	10.22

Financial Efficiency

Return on equity (ROE) is 50.86% and return on invested capital (ROIC) is 11.07%.

Return on Equity (ROE)	50.86%
Return on Assets (ROA)	7.79%
Return on Invested Capital (ROIC)	11.07%
Return on Capital Employed (ROCE)	16.63%
Revenue Per Employee	2.40B
Profits Per Employee	1.04B
Employee Count	241
Asset Turnover	0.64
Inventory Turnover	0.37

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +12.59% in the last 52 weeks. The beta is 0.94, so KRX:326030's price volatility has been similar to the market average.

Beta (5Y)	0.94
52-Week Price Change	+12.59%
50-Day Moving Average	98,914.00
200-Day Moving Average	106,514.00
Relative Strength Index (RSI)	45.59
Average Volume (20 Days)	246,373

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KRX:326030 had revenue of KRW 578.00 billion and earned 251.21 billion in profits. Earnings per share was 3,207.77.

Revenue	578.00B
Gross Profit	536.35B
Operating Income	111.72B
Pretax Income	85.17B
Net Income	251.21B
EBITDA	129.41B
EBIT	111.72B
Earnings Per Share (EPS)	3,207.77

Full Income Statement

Balance Sheet

The company has 268.69 billion in cash and 124.66 billion in debt, giving a net cash position of 144.03 billion or 1,839.21 per share.

Cash & Cash Equivalents	268.69B
Total Debt	124.66B
Net Cash	144.03B
Net Cash Per Share	1,839.21
Equity (Book Value)	591.47B
Book Value Per Share	7,246.94
Working Capital	276.72B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 99.77 billion and capital expenditures -1.41 billion, giving a free cash flow of 98.36 billion.

Operating Cash Flow	99.77B
Capital Expenditures	-1.41B
Free Cash Flow	98.36B
FCF Per Share	1,255.94

Full Cash Flow Statement

Margins

Gross margin is 92.79%, with operating and profit margins of 19.33% and 43.46%.

Gross Margin	92.79%
Operating Margin	19.33%
Pretax Margin	14.74%
Profit Margin	43.46%
EBITDA Margin	22.39%
EBIT Margin	19.33%
FCF Margin	17.02%

Dividends & Yields

KRX:326030 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	3.45%
FCF Yield	1.35%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

KRX:326030 has an Altman Z-Score of 11.9.

Altman Z-Score	11.9
Piotroski F-Score	n/a